Domestic strength, US weakness: Why Indian pharma's FY26 growth story is a two-speed race

India’s pharmaceutical sector is heading into FY26 with optimism at home but uncertainty abroad. Rating agency ICRA, as reported by ANI, projects industry-wide revenue growth of 7–9 percent, powered by robust demand in India and steady trac
Read more...